美国国家医院与门诊医疗护理调查中类风湿关节炎改善病情抗风湿药使用相关因素
该研究分析2005至2014年美国国家门诊医疗护理调查中1405次类风湿关节炎就诊记录,60.4%被处方改善病情抗风湿药(DMARD),23.8%被处方生物制剂DMARD。专科医生就诊与Medicare医保与任何DMARD及生物制剂DMARD使用相关,而种族/族裔与DMARD使用无关。
要点
- 1405次类风湿关节炎就诊中,60.4%被处方DMARD,23.8%被处方生物制剂DMARD。
- 专科医生就诊使用任何DMARD的比值比是普通医生的2.38倍(95%CI 1.37-4.14)。
- Medicare受益者使用任何DMARD的比值比是私人保险者的2.31倍(95%CI 1.40-3.82)。
核心结论
- 专科医生就诊和Medicare受益者与任何DMARD或生物制剂DMARD使用显著相关。
- 与既往证据相反,种族/族裔与任何DMARD或生物制剂DMARD使用无关,可能提示治疗可及性差异减少。
研究设计与样本
- 分析2005至2014年美国国家门诊医疗护理调查中记录的类风湿关节炎就诊数据。
- 共纳入1405次类风湿关节炎诊断就诊记录。
- 主要结局为DMARD使用(传统和/或生物制剂),采用logistic回归模型,协变量包括年龄、性别、种族/族裔、医保类型、医生类型、地理区域和合并症数量。
主要发现
- 1405次就诊中,60.4%(n=807)被处方DMARD,23.8%(n=334)被处方生物制剂DMARD。
- 完全调整模型中,女性使用任何DMARD的比值比是男性的1.57倍(95%CI 1.02-2.46)。
- Medicare受益者使用任何DMARD的比值比是私人保险者的2.31倍(95%CI 1.40-3.82)。
- 专科医生就诊使用任何DMARD的比值比是普通医生的2.38倍(95%CI 1.37-4.14)。
- Medicare受益者使用生物制剂DMARD的比值比是私人保险者的2.58倍(95%CI 1.42-4.70);专科医生就诊使用生物制剂DMARD的比值比是普通医生的3.37倍(95%CI 1.40-8.23)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We examined the treatment patterns among adults with rheumatoid arthritis (RA) and identified factors influencing access to traditional and biological disease modifying antirheumatic drugs (DMARDs). METHODS: We analyzed visits recorded in the National Ambulatory Medical Care Survey from 2005 to 2014 with a RA diagnosis. The primary outcome was DMARD use (traditional and/or biological). We included prescriptions of all RA-related treatments such as traditional and biological DMARDs, glucocorticoids, gold preparations, immunosuppressants, and non-steroidal anti-inflammatory drugs. Covariates in the logistic regression models included age, gender, race/ethnicity, type of health care coverage, provider type, geographic region, and number of comorbidities. RESULTS: Among 1405 visits with a RA diagnosis, 60.4% (n = 807) were prescribed DMARDs and 23.8% (n = 334) biological DMARDs. In fully adjusted models, females have 1.57 times higher odds of any DMARD use (95% confidence interval (CI): 1.02-2.46). Also, Medicare beneficiaries as compared to privately insured have 2.31 times higher odds of receiving any DMARDs (95% CI: 1.40-3.82), while visits with specialist vs. general physician are 2.38 times more associated with any DMARD use (95% CI: 1.37-4.14). For biological DMARDs, Medicare beneficiaries were at 2.58 times higher odds (95% CI: 1.42-4.70) than privately insured, while visits with specialist are at 3.37 times higher odds than general physician (95% CI: 1.40-8.23). CONCLUSION: Visits with a specialist and Medicare beneficiaries were significantly associated with any DMARD or biological DMARD use. Additionally, contrary to prior evidence, race/ethnicity was not associated with any DMARD or biological DMARD use, which may indicate reduction in disparity of treatment access.
引用
- Gaitonde P, Bozzi LM, Shaya FT, et al. Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey. Semin Arthritis Rheum. 2017. PMID: 29153870. doi:10.1016/j.semarthrit.2017.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。